LeMaitre Vascular, Inc. — Q1 2014 Form 10-Q
Business context and reporting period
LeMaitre develops, manufactures, and sells medical devices and implants primarily for vascular surgery. This filing covers the three months ended March 31, 2014; comparisons are with Q1 2013 unless noted. The company operates as one segment and sells primarily through its direct sales force.
Financial performance and liquidity
| Metric | Q1 2014 | Q1 2013 / comparison |
|---|---|---|
| Net sales | $16.754 million | $15.382 million; up 9% |
| Gross profit / margin | $11.224 million / 67.0% | $11.206 million / 72.9% |
| Operating income (loss) | $(0.231) million | $1.123 million |
| Net income (loss) | $(0.207) million; $(0.01) per diluted share | $0.846 million; $0.05 per diluted share |
| Operating cash flow | $(1.689) million | $(0.346) million |
| Cash and equivalents | $12.504 million at March 31 | $14.711 million at December 31, 2013 |
Amounts in the table are in U.S. dollars. Investing cash outflow was $0.639 million, mainly capital spending and distributor buyouts; financing provided $0.123 million. Cash declined $2.207 million during the quarter. Current assets were $40.335 million and current liabilities $8.709 million at quarter-end. The balance sheet reports no interest-bearing debt. Operating leases and inventory purchase commitments totaled $12.365 million, including $3.888 million of inventory commitments.
Material changes versus prior year
- International sales rose 19% to $6.090 million; Americas sales increased 4% to $10.664 million. Growth was led by biologic vascular patches, powered phlebectomy, and valvulotomes. Acquisitions contributed $0.6 million of sales.
- Gross profit was nearly flat despite sales growth, while gross margin fell 5.9 percentage points to 67.0%. Management attributed the decline to manufacturing cost increases, product and geographic mix, biologic-patch manufacturing start-up costs, and Clinical Instruments facility costs; higher selling prices partly offset these pressures.
- Operating expenses increased 14% to $11.455 million. The quarter included $0.403 million of restructuring charges, and general and administrative and sales and marketing costs also increased.
- Operating cash use increased, mainly because of higher inventory and lower accounts payable and other liabilities, including annual compensation payments.
Outlook, commentary, and risks
- Management expects cash and cash equivalents, investments, and related interest earnings to cover anticipated cash needs for at least 12 months. No specific revenue or earnings guidance was provided.
- The company expects 2014 gross margin to be pressured by the XenoSure manufacturing transition. It anticipates potential XenoSure margin improvement beginning in 2015 and improvement from moving Clinical Instruments production to Burlington beginning in Q2 2014; both depend on successful execution.
- Management expected higher 2014 sales and marketing expenses from direct-sales expansion in Australia and Norway, and higher general and administrative costs from establishing a China office. An additional April workforce reduction was expected to cost $0.1–$0.2 million, mostly in Q2.
- Key risks include manufacturing-transfer delays, added costs or product shortages; failure to realize restructuring or acquisition benefits; demand, market acceptance, and competitive pressures; and foreign-currency movements. Management noted that lower-margin products and sales in some international markets could pressure gross margin.
- German and French tax audits were announced, with commencement expected in 2014; management did not expect material changes to tax liabilities. Unrecognized tax benefits were $0.162 million. Management reported no legal matters expected to have a material adverse effect and no substantive changes to previously disclosed risk factors.
Important facts for investors to verify
- Whether sales growth continues and the contribution from acquired products versus existing product lines.
- Whether gross margin stabilizes as manufacturing transfers proceed, particularly for XenoSure and Clinical Instruments.
- Whether restructuring and direct-sales expansion deliver expected savings and growth without disrupting supply or increasing costs beyond expectations.
- Cash conversion and working-capital trends, including inventory growth and cash needs for dividends, acquisitions, and contractual commitments.
- Results and potential financial effects of the announced tax audits and the contingent consideration tied to InaVein.